Business
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations SAN DIEGO and TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-base
About this update from Hanmi Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Aptose Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aptose Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dL_gapQCtA7xgCLWJXAd4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d","width":300,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction ","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations","length":189,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":283,"olType":false},{"type":"text","content":"SAN DIEGO and TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today provided a corporate update and announced the financial results for the year ended December 31, 2025.","length":423,"tagName":"p"},{"type":"text","content":"“We are pleased that shareholders have approved our proposed arrangement with Hanmi, which enables us to continue and expand the development of the TUS+VEN+AZA triplet, which has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. “We are extremely grateful for Hanmi’s ongoing support, including its significant financial support under difficult circumstances over the past two years. The data in our clinical trial continue to support the promise of TUS+VEN+AZA therapy, and we look forward to presenting the next set of data at the EHA2026 Congress in June.” ","length":750,"tagName":"p"},{"type":"text","content":"Corporate Update","length":16,"t...